SPORE in Genitourinary Cancer

描述（由申请人提供）： 这所德克萨斯大学的总体目标是M。D.安德森癌症中心泌尿生殖道孢子在膀胱癌是促进创新的转化研究，在预防，检测和治疗这种疾病，导致消除膀胱癌作为一个主要的健康问题。我们投资了几个主要的转化研究主题：鉴定称为“先导”的一类新基因，其参与癌症发展先于主要肿瘤抑制基因的功能丧失，通过分子流行病学鉴定具有发展膀胱癌或治疗后复发的增加的遗传和/或获得风险的人，开发针对晚期疾病的靶向膀胱癌疗法，以及开发针对浅表疾病的改进疗法。为了实现这些目标，我们的SPORE汇集了临床医生和基础科学家，包括泌尿科医生，医学肿瘤学家，病理学家，分子流行病学家，分子和细胞生物学家，生物统计学家以及新技术和信息学开发专家。SPORE包括4个相互关联的项目，涉及1）膀胱癌的早期检测，2）膀胱癌的风险评估，3）膀胱癌中表皮生长因子受体的生物学和治疗靶向，以及4）通过腺病毒介导的基因治疗改善浅表性膀胱癌的治疗。这些项目由4个核心支持：（A）行政;（B）病理学和组织资源;（C）。生物统计学和生物信息学;（D）临床试验和数据管理。所有的科学项目都是翻译性质的;专注于人类膀胱癌;涉及临床和基础研究人员和生物统计学家;与其他项目互动;并利用核心资源。创新的发展和职业发展项目带来了新的调查人员，并刺激了在每个主要项目中所代表的SPORE。该SPORE解决了所有形式的膀胱癌患者面临的临床困境，并将为更大的努力提供关键组成部分，以制定有效的化学预防，检测，分子分析和治疗，生物免疫治疗，化疗，支持性护理和社区意识策略。实现本提案的目的和目标将导致膀胱癌的发病率、发病率和死亡率大幅下降。

DESCRIPTION (provided by applicant): The overall goal of this University of Texas M. D. Anderson Cancer Center Genitourinary SPORE in Bladder Cancer is to facilitate innovative translational research in the prevention, detection, and treatment of this disease leading to the elimination of bladder cancer as a major health problem. We have invested in several major translational research themes: identification of a novel class of genes referred to as "forerunners" whose involvement precedes the loss of function of major tumor suppressor genes in the development of cancer, identification of persons with an increased inherited and/or acquired risk of developing bladder cancer or recurring following therapy by molecular epidemiology, developing targeted bladder cancer therapies for advanced disease, and the development of improved therapy for superficial disease. To achieve these goals, our SPORE has assembled clinicians and basic scientists including urologists, medical oncologists, pathologists, molecular epidemiologists, molecular and cell biologists, biostatisticians, and experts in development of new technologies and informatics. The SPORE includes 4 inter-related projects that deal with 1) early detection of bladder cancer, 2) risk assessment for bladder cancer 3) biology and therapeutic targeting of the epidermal growth factor receptor in bladder cancer, and 4) improving therapy for superficial bladder cancer through adenoviral mediated gene therapy. These projects are supported by 4 Cores: (A) Administrative; (B) Pathology & Tissue Resources; (C). Biostatistics and Bioinformatics; and (D) Clinical Trials and Data Management. All of the scientific projects are translational in nature; focus on human bladder cancer; involve clinical and basic investigators and biostatisticians; interact with the other projects; and utilize Core resources. Innovative Developmental and Career Development Projects have brought new investigators into and stimulated the SPORE that is represented in each of the major projects. This SPORE addresses clinical dilemmas facing patients with all forms of bladder cancer, and will provide a critical component of a larger effort to develop effective strategies for chemoprevention, detection, molecular profiling and therapeutics, bioimmunotherapy, chemotherapy, supportive care, and community awareness. Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of bladder cancer.